Abbott Laboratories (ABT) Cash & Equivalents (2009 - 2026)

Abbott Laboratories has disclosed Cash & Equivalents across 18 years of filings, most recently posting $6.8 billion for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $6.8 billion, up 4.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.8 billion (up 4.15% YoY), and the FY2025 annual result was $8.5 billion, up 11.9% from the prior year.
• Cash & Equivalents came in at $6.8 billion for Q1 2026 at Abbott Laboratories, down from $8.5 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $9.9 billion in Q4 2022 to a low of $6.3 billion in Q1 2024.
• The 5-year median for Cash & Equivalents is $7.6 billion (2024), against an average of $7.7 billion.
• Across the five-year window, Cash & Equivalents rose 19.36% in 2023 and tumbled 31.4% in 2024, its largest moves.
• Abbott Laboratories' Cash & Equivalents stood at $9.9 billion in 2022, then tumbled by 30.22% to $6.9 billion in 2023, then climbed by 10.44% to $7.6 billion in 2024, then rose by 11.9% to $8.5 billion in 2025, then fell by 20.17% to $6.8 billion in 2026.
• The last three Cash & Equivalents figures came in at $6.8 billion (Q1 2026), $8.5 billion (Q4 2025), and $7.5 billion (Q3 2025), per Business Quant data.